Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
75 participants
OBSERVATIONAL
2020-07-31
2021-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Psoriasis vulgaris is the most common type, and accounts 90% of cases. Patients with psoriasis vulgaris present with pain, itching and bleeding from skin lesions.
There are many theories for psoriasis pathogenesis: angiogenesis, decrease in apoptosis of keratinocyte, hyperproliferation , alteration of cell to cell adhesion and immune-mediated inflammation.
Patients with immune mediated inflammatory disease (IMID) are susceptible to develop diabetes mellitus, metabolic syndrome, hyperlipidemia, and hypertension.A previous study found that psoriatic patients are more susceptible to type 2 diabetes compared to control.
Glucose transporter type 1(GLUT1) is upregulated in psoriatic patient attributed to angiogenesis and execessive cell proliferation in those patients .Also expression of GLUT 1 is found high with hyperglycemia . A study reported that GLUT 1 density in placenta of women with gestational diabetes was found to be two folds higher than control.
Pigment epithelium derived factor (PEDF) has antiangiogenic effect. Topical application of PEDF on mouse model of psoriatic disease helps in reduction of skin proliferation and angiogenesis.
GLUT 1 overexpression was found to be associated with decrease in PEDF expression in diabetic retinopathy.
In view of that we will compare the level of GLUT 1 gene in psoriatic patients and psoriatic patients with diabetes, as well as healthy control, and detect the effect of PEDF on GLUT 1 expression in vitro using human keratinocytes cell line .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Insulin Action in Psoriasis Pathogenesis
NCT06242847
Incretin Effect in Patients With Psoriasis and Controls
NCT06064084
Efficacy and Safety Study of Total Glucosides of Paeony Combined With Acitretin to Treat Psoriasis
NCT02191020
Dietary Approach to Mild-to-moderate Psoriasis
NCT05644782
Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis
NCT05590247
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with psoriasis vulgaris only
GLUT 1 gene expression
GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.
Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment.
patients with psoriasis vulgaris and type 2 diabetes mellitus
GLUT 1 gene expression
GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.
Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment.
healthy control
GLUT 1 gene expression
GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.
Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GLUT 1 gene expression
GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.
Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SSElkady
Demonstrator at Medical Biochemistry department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Naglaa K Idriss, asst. prof
Role: STUDY_DIRECTOR
Assiut University
Ayaat ِA Sayed, asst. prof
Role: STUDY_DIRECTOR
Assiut University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Abdou AG, Maraee AH, Eltahmoudy M, El-Aziz RA. Immunohistochemical expression of GLUT-1 and Ki-67 in chronic plaque psoriasis. Am J Dermatopathol. 2013 Oct;35(7):731-7. doi: 10.1097/DAD.0b013e3182819da6.
Sondermann W, Djeudeu Deudjui DA, Korber A, Slomiany U, Brinker TJ, Erbel R, Moebus S. Psoriasis, cardiovascular risk factors and metabolic disorders: sex-specific findings of a population-based study. J Eur Acad Dermatol Venereol. 2020 Apr;34(4):779-786. doi: 10.1111/jdv.16029. Epub 2019 Dec 3.
Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016 Jun 14;3(1):79-82. doi: 10.14744/nci.2016.16023. eCollection 2016.
Holm JG, Thomsen SF. Type 2 diabetes and psoriasis: links and risks. Psoriasis (Auckl). 2019 Jan 17;9:1-6. doi: 10.2147/PTT.S159163. eCollection 2019.
Granata M, Skarmoutsou E, Trovato C, Rossi GA, Mazzarino MC, D'Amico F. Obesity, Type 1 Diabetes, and Psoriasis: An Autoimmune Triple Flip. Pathobiology. 2017;84(2):71-79. doi: 10.1159/000447777. Epub 2016 Sep 17.
Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol. 2017 Aug;18(4):583-590. doi: 10.1007/s40257-017-0274-0.
Li Y, Song Y, Zhu L, Wang X, Yang B, Lu P, Chen Q, Bin L, Deng L. Interferon Kappa Is Up-Regulated in Psoriasis and It Up-Regulates Psoriasis-Associated Cytokines in vivo. Clin Cosmet Investig Dermatol. 2019 Nov 29;12:865-873. doi: 10.2147/CCID.S218243. eCollection 2019.
Matsuura T, Sato M, Nagai K, Sato T, Arito M, Omoteyama K, Suematsu N, Okamoto K, Kato T, Soma Y, Kurokawa MS. Serum peptides as putative modulators of inflammation in psoriasis. J Dermatol Sci. 2017 Jul;87(1):36-49. doi: 10.1016/j.jdermsci.2017.03.014. Epub 2017 Mar 27.
Lee JH, Kim JS, Park SY, Lee YJ. Resveratrol induces human keratinocyte damage via the activation of class III histone deacetylase, Sirt1. Oncol Rep. 2016 Jan;35(1):524-9. doi: 10.3892/or.2015.4332. Epub 2015 Oct 16.
Shaker O, Abdel-Halim M. Connexin 26 in psoriatic skin before and after two conventional therapeutic modalities: methotrexate and PUVA. Eur J Dermatol. 2012 Mar-Apr;22(2):218-24. doi: 10.1684/ejd.2012.1649.
Gaither K, Quraishi AN, Illsley NP. Diabetes alters the expression and activity of the human placental GLUT1 glucose transporter. J Clin Endocrinol Metab. 1999 Feb;84(2):695-701. doi: 10.1210/jcem.84.2.5438.
Calado SM, Alves LS, Simao S, Silva GA. GLUT1 activity contributes to the impairment of PEDF secretion by the RPE. Mol Vis. 2016 Jul 14;22:761-70. eCollection 2016.
Abe R, Yamagishi S, Fujita Y, Hoshina D, Sasaki M, Nakamura K, Matsui T, Shimizu T, Bucala R, Shimizu H. Topical application of anti-angiogenic peptides based on pigment epithelium-derived factor can improve psoriasis. J Dermatol Sci. 2010 Mar;57(3):183-91. doi: 10.1016/j.jdermsci.2009.12.010. Epub 2010 Jan 8.
Pyla R, Poulose N, Jun JY, Segar L. Expression of conventional and novel glucose transporters, GLUT1, -9, -10, and -12, in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2013 Mar;304(6):C574-89. doi: 10.1152/ajpcell.00275.2012. Epub 2013 Jan 9.
Shurman DL, Glazewski L, Gumpert A, Zieske JD, Richard G. In vivo and in vitro expression of connexins in the human corneal epithelium. Invest Ophthalmol Vis Sci. 2005 Jun;46(6):1957-65. doi: 10.1167/iovs.04-1364.
Mohany KM, Elkady S, Youssef EMK, Sayed NM, Idriss NK. Pigment epithelium-derived factor (PEDF) represses the glucose transporter 1 (GLUT1) mRNA expression and may be a potential therapeutic agent in psoriasis: a case-control and experimental study. Sci Rep. 2023 Dec 5;13(1):21424. doi: 10.1038/s41598-023-48565-9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PGLUTPEDF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.